

EQA round: AIH2/23 - Autoimmune Liver Diseases

Deadline: 20.10.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
(451) AMA		52			52	51	98	
Sample A		52			52	52	100	
(1) Fluorescent methods	CVP >>>	52	100	Negative				
Sample B		52			52	51	98	
(1) Fluorescent methods		1	1,9	Negative				
	CVP >>>	51	98	Positive				
(456) AMA-M2		62			62	62	100	
Sample A		62			62	62	100	
(1) Fluorescent methods	CVP >>>	1	1,6	Negative				
(2) EIA methods	CVP >>>	10	16	Negative				
(5) Immunoblotting	CVP >>>	51	82	Negative				
Sample B		62			62	62	100	
(1) Fluorescent methods	CVP >>>	1	1,6	Positive				
(2) EIA methods	CVP >>>	10	16	Positive				
(5) Immunoblotting	CVP >>>	51	82	Positive				
(454) anti-gp210		51			51	48	94	
Sample A		51			51	50	98	
(2) EIA methods	CVP >>>	1	2	Negative				
(5) Immunoblotting	CVP >>>	49	96	Negative				
		1	2	Inconclusive result (borderline)				
Sample B		51			51	48	94	
(2) EIA methods	CVP >>>	1	2	Negative				
(5) Immunoblotting	CVP >>>	47	92	Negative				
		3	5,9	Inconclusive result (borderline)				
(457) anti-LC-1		59			59	59	100	
Sample A		59			59	59	100	
(2) EIA methods	CVP >>>	4	6,8	Negative				
(5) Immunoblotting	CVP >>>	55	93	Negative				
Sample B		59			59	59	100	
(2) EIA methods	CVP >>>	4	6,8	Negative				
(5) Immunoblotting	CVP >>>	55	93	Negative				
(452) anti-LKM		47			47	46	98	
Sample A		47			47	47	100	
(1) Fluorescent methods	CVP >>>	45	96	Negative				
(5) Immunoblotting	CVP >>>	2	4,3	Negative				
Sample B		47			47	46	98	
(1) Fluorescent methods	CVP >>>	44	94	Negative				
		1	2,1	Inconclusive result (borderline)				
(5) Immunoblotting	CVP >>>	2	4,3	Negative				
(455) anti-LKM1		62			62	62	100	
Sample A		62			62	62	100	
(1) Fluorescent methods	CVP >>>	1	1,6	Negative				
(2) EIA methods	CVP >>>	10	16	Negative				
(5) Immunoblotting	CVP >>>	51	82	Negative				
Sample B		62			62	62	100	
(1) Fluorescent methods	CVP >>>	1	1,6	Negative				
(2) EIA methods	CVP >>>	10	16	Negative				
(5) Immunoblotting	CVP >>>	51	82	Negative				
(458) anti-SLA		61			61	61	100	
Sample A		61			61	61	100	
(2) EIA methods	CVP >>>	8	13	Negative				
(5) Immunoblotting	CVP >>>	53	87	Negative				
Sample B		61			61	61	100	
(2) EIA methods	CVP >>>	8	13	Negative				
(5) Immunoblotting	CVP >>>	53	87	Negative				
(459) anti-sp100		51			51	43	84	
Sample A		51			51	43	84	
(2) EIA methods		1	2	Negative				
(5) Immunoblotting		3	5,9	Negative				
		4	7,8	Inconclusive result (borderline)				
	CVP >>>	43	84	Positive				
Sample B		51			51	51	100	
(2) EIA methods	CVP >>>	1	2	Positive				
(5) Immunoblotting	CVP >>>	50	98	Positive				

EQA round: AIH2/23 - Autoimmune Liver Diseases

Deadline: 20.10.2023

Setup: groups - measurement principle

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(453) SMA		54			54	54	100
Sample A		54			54	54	100
(1) Fluorescent methods	CVP >>>	53	98	Negative			
(5) Immunoblotting	CVP >>>	1	1,9	Negative			
Sample B		54			54	54	100
(1) Fluorescent methods	CVP >>>	53	98	Negative			
(5) Immunoblotting	CVP >>>	1	1,9	Negative			